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Abstract
The existence of a hypothalamic gonadotropin-inhibiting system has been elusive. A neuropeptide named gonadotropin-
inhibitory hormone (GnIH, SIKPSAYLPLRF-NH2) which directly inhibits gonadotropin synthesis and release from the pituitary
was recently identified in quail hypothalamus. Here we identify GnIH homologs in the human hypothalamus and
characterize their distribution and biological activity. GnIH homologs were isolated from the human hypothalamus by
immunoaffinity purification, and then identified as MPHSFANLPLRF-NH2 (human RFRP-1) and VPNLPQRF-NH2 (human RFRP-
3) by mass spectrometry. Immunocytochemistry revealed GnIH-immunoreactive neuronal cell bodies in the dorsomedial
region of the hypothalamus with axonal projections to GnRH neurons in the preoptic area as well as to the median
eminence. RT-PCR and subsequent DNA sequencing of the PCR products identified human GnIH receptor (GPR147) mRNA
expression in the hypothalamus as well as in the pituitary. In situ hybridization further identified the expression of GPR147
mRNA in luteinizing hormone producing cells (gonadotropes). Human RFRP-3 has recently been shown to be a potent
inhibitor of gonadotropin secretion in cultured sheep pituitary cells by inhibiting Ca2+ mobilization. It also directly
modulates GnRH neuron firing. The identification of two forms of GnIH (RFRP-1 and RFRP-3) in the human hypothalamus
which targets human GnRH neurons and gonadotropes and potently inhibit gonadotropin in sheep models provides a new
paradigm for the regulation of hypothalamic-pituitary-gonadal axis in man and a novel means for manipulating
reproductive functions.
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Introduction
Gonadotropin-releasing hormone (GnRH) is the primary
stimulator of gonadotropin secretion [1–5]. A neuropeptide
inhibitor of gonadotropin secretion has also been postulated
[6–8]. The recent identification of an avian hypothalamic
dodecapeptide that inhibits pituitary gonadotropin release implies
that such a factor might exist in vertebrates [9]. This factor, named
gonadotropin-inhibitory hormone (GnIH), is synthesized in
neurons of the paraventricular nucleus (PVN) in birds [9–13].
The GnIH neurons project to the median eminence, providing
neuroanatomical infrastructure to allow secretion into the
hypophysial portal system and thus regulate pituitary function
[9–13]. The cognate G protein-coupled receptor (GPCR) for
GnIH was also identified in the quail pituitary [14] and GnIH was
shown to act on the pituitary to suppress synthesis and release of
gonadotropins [15]. Accordingly, GnIH inhibits the development
and maintenance of gonadotropin-dependent gonadal functions
[16]. Thus, while GnIH serves an important physiological role in
birds [9–19], there has been limited evidence that the same is true
for mammals.
GnIH homologs are present in the brains of non-human
vertebrates, including mammals, amphibians and fish [20,21].
These peptides belong to the RFamide-related peptide (RFRP)
[22] family and possess a characteristic C-terminal LPXRFamide
(X =L or Q) motif [20,21]. The receptors for GnIH homologs
have also been characterized in vertebrates [14,20–22]. Quail
GnIH and rat GnIH peptide homolog, RFRP-3, inhibits
luteinizing hormone (LH) secretion in Syrian hamsters [23]
and rats [24,25] in vivo. It was recently shown that RFRP-3
inhibits pulsatile gonadotropin release in vivo as well as from
cultured pituitary cells in sheep [26,27] and cattle [28],
suggesting that a hypothalamic gonadotropin-inhibitory system
also exists in mammals. Accordingly, a GnIH/RFRP system
might be a conserved property of vertebrates. However, these
mammalian GnIH peptide homologs were inferred from
genomic sequences and the processed peptides have yet to be
unequivocally identified.
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Here we first analyzed the existence of GnIH-immunoreactive
(-ir) material in human hypothalamus by immunocytochemistry
(ICC). We further investigated whether there were interactions of
GnIH-ir neurons with GnRH neurons by double-label ICC. We
then isolated human GnIH peptide homologs (human RFRP-1
and RFRP-3) by immunoaffinity purification and identified the
structure of the peptides by mass spectrometry. A G-protein
coupled receptor, GPR147 (OT7T022) has been identified as the
cognate receptor for RFRPs in studies investigating the role of
these peptides in the central nervous system [29]. Accordingly
GPR147 mRNA expression was analyzed in the hypothalamus
and the pituitary by RT-PCR and DNA sequencing of the PCR
products. In situ hybridization further revealed the expression of
GPR147 mRNA in pituitary cells including luteinizing hormone
(LH) producing cells. The human RFRP-3 was recently shown to
potently inhibit GnRH stimulation of gonadotropin secretion from
sheep in vivo and from cultured gonadotropes through inhibition of
Ca2+ mobilization [26]. The identification of RFRP-1 and RFRP-
3 and the cognate receptor GPR147 along with the demonstration
of gonadotropin inhibition prompts revision of our understanding
of the central control mechanism of human reproduction.
Results
Localization of GnIH-ir neurons in the human
hypothalamus
ICC using avian GnIH antibody identified a group of GnIH-ir
neurons in the dorsomedial region of the human hypothalamus
(Fig. 1A, 1B). Some GnIH-ir fibers emanated from the infundib-
ulum of the hypothalamus (Fig. 1A) and terminated in the external
layer of the median eminence (Fig. 1C). GnIH-ir neuronal axon
terminal-like structures were further observed on GnRH neurons in
the preoptic area (Fig. 1D).
Identification of mature human GnIH peptide homologs
We identified the fully processed forms of GnIH homologs in
the extract of human hypothalamus by using an avian GnIH
antibody-conjugated immunoaffinity column and mass spectrom-
etry. The human genome database revealed that a putative
homolog of the GnIH precursor polypeptide gene is present in
humans (GenBank NM_022150; 29), but the processed peptide
products had not been identified until now. Because of several
potential cleavage sites in the putative GnIH precursor polypep-
tide (Fig. 2A), there were various possible GnIH peptide products.
Thus, based on the human genome, putative human RFRP-1
could be 12, 20, 24, 29, 37, 40, 44, 49 or 54 amino acids in length
and human RFRP-3 could be 8 or 31 amino acids in length
(Fig. 2A). Hypothalamic tissue from adult men and women was
used to purify and identify human RFRP peptides by immunoaf-
finity purification followed by MALDI-TOF MS. GnIH-ir
material in the extract of human hypothalamus showed a
molecular ion peak of 1428.85 m/z ([M+H]+) (Fig. 2B). This
value was in accord with the theoretical mass of the predicted
human RFRP-1 (MPHSFANLPLRF-NH2) [1428.75 m/z
([M+H]+)]. GnIH antiserum isolated another immunoreactive
material in the hypothalamic extracts with a molecular ion peak of
969.48 m/z ([M+H]+) (Fig. 2C). This value was in accord with the
theoretical mass of the predicted human RFRP-3 (VPNLPQRF-
NH2) [969.56 m/z ([M+H]+)]. To confirm the data obtained by
MALDI-TOF MS analyses of the endogenous GnIH-ir material,
peptides having the suggested sequences were synthesized and
compared with the native peptides for retention time on reverse-
phase high performance liquid chromatography (HPLC) and mass
number. Both native and synthetic peptides showed a similar
retention time using HPLC and a similar molecular mass [RFRP-
1: 1428.91 m/z ([M+H]+), RFRP-3: 969.81 m/z ([M+H]+)]
(Table 1). Furthermore, fragmentation of the synthetic and native
peptides by tandem MS confirmed the structures of human
RFRP-1 and RFRP-3.
Expression of GPR147 mRNA in the human
hypothalamus and in the pituitary
The expression of human RFRP receptor, GPR147, mRNA
was analyzed in the human hypothalamus as well as in the
pituitary. Combinations of various forward primers (F1, F2 and
F3) and a reverse primer (R) produced expected RT-PCR
products of 479, 415 and 325 bp in the hypothalamus (Fig. 3).
The PCR products were sequenced and confirmed to be derived
from GPR147 mRNA (GenBank NM_022146). RT-PCR and
subsequent DNA sequencing of the PCR products also identified
the same 479, 415 and 325 bp GPR147 cDNAs expressed in the
pituitary. F1/R and F3/R primer combinations produced
additional RT-PCR products in the pituitary; DNA sequencing
identified that they were derived from Homo sapiens RAB11 family
interacting protein 1 and NEDD4 binding protein 1 mRNAs,
respectively. In situ hybridization using an antisense RNA probe
for GPR147 mRNA in conjunction with ICC for human LH
showed the expression of GPR147 mRNA in the gonadotrope of
the adult human anterior pituitary (Fig. 1, E and F). In situ
hybridization using sense RNA probe (Fig. 1G) and immunocy-
tochemistry without LH primary antiserum (Fig. 1H) served as
controls.
Discussion
We identified the fully processed forms of GnIH homologs in an
extract of human hypothalamus by using an avian GnIH
antibody-conjugated immunoaffinity column and mass spectrom-
etry. Two GnIH homologs were identified, the structures of
which were MPHSFANLPLRF-NH2 (human RFRP-1) and
VPNLPQRF-NH2 (human RFRP-3). The human genome
database also predicted the presence of an RFRP-like peptide
which has a C-terminus LPLRSamide motif, but this was not
detected, possibly because of the difference in the C-terminal
amino acid compared to avian GnIH, or because this peptide is
not processed from the precursor. The precise mechanism of how
the GnIH/RFRP precursor protein is processed into mature
peptides and how this process differs between species is unknown.
GnIH-ir neurons were observed in the dorsomedial region of
the human hypothalamus. The location of GnIH neuronal cell
bodies were in general agreement to hamsters (dorsomedial
hypothalamus; 23) and sheep (dorsomedial hypothalamic nucleus
and paraventricular nucleus; 26). GnIH-ir axon terminal like
structures were observed in close proximity to GnRH neurons in
the preoptic area suggesting the regulation of GnRH neurons by
GnIH. The interaction of GnIH-ir fibers with GnRH neurons is
consistent with results in birds [17,19], rodents [23] sheep [31] and
monkey [32]. In starlings, GnIH receptor (GPR147) mRNA is
expressed in GnRH neurons [19] and we demonstrated expression
of the GPR147 in human hypothalamus. The possibility that
GnIH affects GnRH neuron activity is supported by the recent
demonstration that RFRP administration reduces the firing
activity [33,34] and immediate early gene expression in GnRH
neurons [35]. GnIH-ir axons also projected to the neurosecretory
zone of the median eminence suggesting that GnIH might also
directly regulate pituitary function. The expression of the human
GPR147 mRNA in the pituitary supports this notion. Moreover,
in situ hybridization for GPR147 mRNA in conjunction with
A Human GnIH
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immunocytochemistry for human LH further showed the
expression of GPR147 mRNA in gonadotropes of the adult
human anterior pituitary. Accordingly, human GnIH homologs
may regulate gonadotropin secretion by inhibiting GnRH neurons
as well as directly acting on gonadotrope cells in the pituitary as
was clearly demonstrated in isolated pituitary cells in the sheep
[26,27].
Our identification of RFRP-1 and RFRP-3 peptides in the
human hypothalamus and the ICC demonstration of targeting
GnRH neurons in the human hypothalamus along with the
expression of GPR147 in human gonadotropes provide a cogent
framework for RFRP regulation of human reproduction. The
question arises as to whether the human RPRP peptides are
biologically active and inhibit gonadotropins. Similarly, we studied
the effects of human RFRP on the mouse gonadotrope LbT2 cell
line but detected no effects on any signaling pathway. When we
checked GPR147 expression by RT-PCR no products were
detected in this immature gonadotrope cell line (data not shown).
We detected inhibitory effects in human fetal pituitary cells, but
these were inconsistent even though they exhibited robust
gonadotropin responses to GnRH (data not shown). This
variability may be due to the immaturity of the gonadotropes.
Figure 1. GnIH immunoreactive neurons in the human hypothalamus and GnIH receptor mRNA in the human pituitary. (A) Coronal
section of adult human hypothalamus showing GnIH immunoreactive (-ir) neurons clustered in the dorsomedial region of the hypothalamus with
their fibers extending to the infundibulum (INF). III, third ventricle. Bar, 1 mm. (B) Higher magnification of GnIH-ir neuronal cell bodies. Bar, 50 mm. (C)
Sagittal section of the median eminence showing dense population of GnIH-ir fibers within the external layer. Bar, 10 mm. (D) GnIH-ir axon terminal
like structures (stained in purple, indicated by black arrows) in close proximity to a GnRH-ir neuronal cell body (stained in brown) in the preoptic area.
Bar, 50 mm. (E and F) In situ hybridization of human GnIH receptor (GPR147) mRNA in the human anterior pituitary (E) in combination with
immunocytochemistry for luteinizing hormone (LH) (F). Red arrows in (E) and white arrows in (F) in equivalent positions show cells which express
both GPR147 mRNA and LH. Bars, 30 mm. (G and H) In situ hybridization using sense RNA probe (G) and immunocytochemistry without LH primary
antiserum (H) served as controls. Bars, 30 mm.
doi:10.1371/journal.pone.0008400.g001
A Human GnIH
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However, human RFRP-3, which is identical in sequence to sheep
RFRP-3, potently inhibits gonadotropin secretion in vivo in sheep
and GnRH stimulation of gonadotropin secretion from cultured
sheep pituitary cells [26,27]. This strongly suggests RFRP-3 would
also be active in the direct inhibition of gonadotropin release from
gonadotropes in man. The demonstration that RFRP regulates
GnRH neuron firing and early gene expression [33–35] suggests
that the peptides may also be effective at this level in man. The
question also arises as to whether RFRP-1 and RFRP-3 have
similar or different functions. It appears from the large pain
literature that they both bind GPR147 with similar affinity and
recruit similar signalling pathways. Thus, the presence of two
peptide products from the same gene may be a means for signal
amplification.
The identification of novel RFamide-related peptides (RFRP-1
and RFRP-3) in the human hypothalamus and the demonstration
that human RFRP-3 has potent inhibitory actions on gonadotro-
pin secretion in animal models opens up new vistas for
understanding the regulation of reproduction. Many factors such
as stress, anorexia, diabetes, obesity and photoperiod inhibit
gonadotropin secretion. The possible role of GnIH in mediating
these effects has been implicated in animal models [30,36,37].
GnRH analogues are extensively employed to manipulate the
hypothalamic-pituitary-gonadal axis in various clinical conditions
[38–40]. In view of its potent inhibition of gonadotropes, GnIH
has the potential of an alternative or adjunct therapeutic agent to
inhibit gonadotropins and steroid hormones. Thus this endoge-
nous inhibitor of gonadotropin secretion has therapeutic potential
in the treatment of hormone-dependent diseases such as
precocious puberty, endometriosis, uterine fibroids, benign
prostatic hyperplasia and prostatic and breast cancers. Human
GnIH may also have potential as a novel contraceptive.
Figure 2. Identification of human GnIH homologs. (A) Amino acid sequence of the human GnIH precursor polypeptide. The arrowhead shows
the predicted cleavage site of the N-terminal secretory signal peptide [29]. Two peptide sequences which have LPXRF (X = L or Q) sequence at their
C-termini with glycine as an amidation signal and arginine as an endoproteolytic basic amino acid are underlined (RFRP-1, RFRP-3). One peptide
sequence which has LPLRS sequence at its C-terminus with glycine and arginine is underlined with a broken line (RFRP-2). The basic amino acids
which could be proteolytic cleavage sites are shown in red. (B) Chromatogram of MALDI-TOF MS of the native human RFRP-1. (C) Chromatogram of
MALDI-TOF MS of the native human RFRP-3.
doi:10.1371/journal.pone.0008400.g002
Table 1. Behavior of Native and Synthetic Human RFRP-1 and RFRP-3 on MALDI-TOF MS.
Observed Mass m/z ([M+H]+) Observed Mass m/z ([M+H]+) Theoretical Mass m/z ([M+H]+)
Native Synthetic
Human RFRP-1 1428.85 1428.91 1428.75
Human RFRP-3 969.48 969.81 969.56
doi:10.1371/journal.pone.0008400.t001
A Human GnIH
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Materials and Methods
Human hypothalamus and pituitary tissue
Frozen and fixed adult human hypothalamus and pituitary
tissue were obtained from Harvard Brain Tissue Resource Center
(Belmont, MA). All donations were with fully informed consent by
written statements from the deceased individuals. The research
was approved by the ethics committee of the Harvard Brain Tissue
Resource Center, McLean Hospital (Belmont, MA) (Director:
Francine M. Benes, M.D., Ph.D.) and the IRB. All procedures
were performed in accordance with the NIH Guide and under an
approved protocol from the University of California.
Immunocytochemistry of human GnIH peptide
Immunocytochemical analysis of GnIH was conducted with
slight modifications of our previous method [19] on coronal
sections at 40 mm thickness of five fixed human hypothalami.
Sections were first post-fixed in 4% PFA for 30 min, and
incubated in 0.3% H2O2 in absolute methanol for 20 min to
suppress endogenous peroxidase activity after washing the sections
three times in phosphate-buffered saline (PBS; 10 mM phosphate
buffer, 0.14 M NaCl, pH 7.4). Sections were washed three times
in PBS and incubated overnight at 4uC in the primary antibody at
a concentration of 1:5,000 in PBS-T (0.2% Triton X-100 in PBS).
The primary antibody used was affinity column purified rabbit
anti-white-crowned sparrow GnIH (SIKPFSNLPLRF-NH2) anti-
body (code: PAC 123/124, G.E.B.). The next day, three
subsequent washes in PBS were followed by incubation in
biotinylated goat anti-rabbit IgG (1:250 in PBS-T) for 1 h. After
washing the sections in PBS-T three times, they were incubated for
1 h in avidin-biotin complex (ABC; Vectastain Elite Kit, Vector
Laboratories, Burlingame, CA) in PBS-T. The resulting complex
was visualized using 0.03% 3,3 diaminobenzidine (DAB) after
washing the sections three times in PBS-T. After the structures of
human GnIH peptides were indentified, the specificity of the
primary antibody was assessed by adsorption tests of the antibody
with 161026 M synthetic human RFRP-1 (MPHSFANLPLRF-
NH2), human RFRP-3 (VPNLPQRF-NH2), human NPAF
(AGEGLNSQFWSLAAPQRF-NH2) and kisspeptin (YNWNS-
FGLRF-NH2). Incubation of the avian GnIH antibody with
161026 M synthetic human RFRP-1 and human RFRP-3 com-
pletely inhibited the staining. However, the staining was not
inhibited by incubating the GnIH antibody with 161026 M
kisspeptin or human NPAF.
Double-labeling immunocytochemistry of GnIH and
GnRH
To determine the relative neuroanatomical distribution of
GnIH and GnRH peptides, double-labeling immunocytochemis-
try of GnIH and GnRH neurons was performed with slight
modifications of our previous method [19]. First, sections were
fixed in 4% PFA for 30 min, and after washing the sections with
PBS three times they were incubated in 0.3% H2O2 in absolute
methanol for 20 min to inactivate endogenous peroxidase activity.
After washing the sections in PBS three times and immersing the
sections in 2% normal goat serum in PBS-T, sections were
incubated overnight at 4uC in the white-crowned sparrow GnIH
antibody in PBS-T at a concentration of 1:5000. The next day,
three subsequent washes in PBS were followed by incubation for
1 h in biotinylated goat anti-rabbit IgG (1:250 in PBS-T). Sections
were then incubated for 1 h in ABC, and the resulting complex
was visualized using Vector VIP (Vector Laboratories). The
primary antibody used to label GnRH neurons was rabbit anti-
GnRH (HU60H; kindly donated by Dr. H. Urbanski) at a
concentration of 1:5000 in PBS-T. The HU60 (bleed H) antiserum
was generated against mammalian GnRH-I (pEHWSYGLRPG-
NH2). HU60 equally recognizes mammalian GnRH-I, avian
GnRH-I (pEHWSYGLQPG-NH2) and salmon GnRH (pEHW-
SYGWLPG-NH2). On the other hand, the antiserum shows no
cross-reactivity with GnRH-free acid or GnRH fragments as well
as other neuropeptides, including growth hormone-releasing
hormone, oxytocin, somatostatin, thyrotropin-releasing hormone
and vasoactive intestinal peptide [41]. The next day, three
subsequent washes in PBS were followed by incubation for 1 h
in biotinylated goat anti-rabbit IgG. Sections were then incubated
for 1 h in ABC, and the resulting complex was visualized using
DAB. Thus GnIH fibers were labeled in purple by Vector VIP,
whereas GnRH neurons were labeled in brown by DAB.
Immunoaffinity purification and mass spectrometry of
human GnIH peptide
To identify the structure of the mature human GnIH peptide, we
first collected GnIH-ir material from brain extract as follows, using
an antiserum raised against quail GnIH [9]. Five frozen human
hypothalami (total weight 5.8 g) were boiled and homogenized in
5% acetic acid, as described previously [42]. The homogenate was
centrifuged at 10,000 g for 30 min at 4uC, and the supernatant was
collected. The collected supernatant was passed through a
disposable C-18 cartridge column (Mega Bond-Elut; Varian,
Harbor, CA, USA). The retained material eluted with 60%
methanol was concentrated by using an evaporator and loaded
onto an immunoaffinity column. The affinity chromatography was
carried out as previously described [43]. The antiserum against
quail GnIH was conjugated to cyanogen bromide-activated
Sepharose 4B (Amersham Pharmacia Biotech, Uppsala, Sweden)
as an affinity ligand. The concentrated material was applied to the
immunoaffinity column at 4uC and the adsorbed materials were
eluted with 0.3 M acetic acid containing 0.1% 2-mercaptoethanol.
The eluted fractions were again concentrated and subjected to a
reversed-phase HPLC column (ODS-80TM; Tosoh, Tokyo, Japan)
with a linear gradient of 10–50% acetonitrile containing 0.1%
trifluoroacetic acid at a flow rate of 0.5 ml/min, and fractionated
every 2 min for 100 min. The immunoreactive fraction was assayed
by a dot immunoblot assay and the molecular mass of the material
was analyzed by matrix-assisted laser desorption/ionization-time-
of-flight-mass spectrometry (MALDI-TOF MS; AXIMA-CFR-
plus, Shimadzu, Kyoto, Japan). MPHSFANLPLRF-NH2 (human
RFRP-1) and VPNLPQRF-NH2 (human RFRP-3) were predicted
Figure 3. Gel image of RT-PCR products of human GnIH
receptor (GPR147) mRNA. cDNAs corresponding to 1 mg total RNA
extracted from human hypothalamus or pituitary were used for a PCR
reaction. Combinations of forward primers (F1, F2 and F3) with a reverse
primer (R) produced RT-PCR products of 479, 415 and 325 bp using
hypothalamic and pituitary cDNAs as the template. The PCR products
were sequenced and confirmed to be derived from GPR147 mRNA
(NM_022146). F1/R and F3/R primer combinations produced additional
RT-PCR products in the pituitary although the subsequent DNA
sequencing identified that they were derived from Homo sapiens
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as the mature peptides from the deduced amino acid sequence of the
human genome sequence. Accordingly, the peptide was synthesized
by using a peptide synthesizer (PSSM-8; Shimadzu) and the
molecular behavior of the synthetic and native peptides was
compared by MALDI-TOF MS. Furthermore, fragmentation of
the synthetic and native peptides were analyzed by tandem MS.
RT-PCR and DNA sequencing of human RFRP receptor
cDNA
One human hypothalamus and one human pituitary were used
for the identification of a cDNA encoding human GPR147. Total
RNA (including rRNA and mRNA) was isolated by using
TRIZOL (Invitrogen, Carlsbad, CA). Total RNA was reverse
transcribed using oligo(deoxythymidine)15 primer (Promega,
Madison, WI) and reverse transcriptase (M-MLV Reverse
Transcriptase; Invitrogen). Partial human GPR147 cDNA was
amplified by PCR using various primers based on human GPR147
cDNA sequence (NM_022146). Combinations of forward primer
1 (F1: 59-ATGTTCATCCTCAACCTGGCTGTC-39), forward
primer 2 (F2: 59-TTGTGGACAACCTCATCACTGGGT-39),
forward primer 3 (F3: 59-TTTTCACACTGGTGGCCATTG-
CTG-39) against a reverse primer (R1: 59-ATGCGGGCGTA-
CATGACCACGATGA-39) produced PCR products. All PCR
amplifications were performed in a reaction mixture containing
Taq polymerase (TaKaRa Ex TaqTM; Takara Bio Inc., Shiga,
Japan). PCR products were sub-cloned into a pGEM-T Easy
vector (Promega) and the DNA inserts of the positive clones were
amplified by PCR with universal M13 primers. Amplified DNA
was sequenced at the UC Berkeley DNA sequencing facility
(Berkeley, CA) using 3730xl DNA Analyzer (Applied Biosystems,
Foster City, CA).
In situ hybridization for human GnIH receptor, GPR147,
mRNA and double staining with LH ICC
Coronal sections at 40 mm thickness of four frozen human
pituitaries were collected on a cryostat at 220uC for histological
studies. In situ hybridization was carried out with slight
modifications of our previous method [36] using a digoxigenin
(DIG)-labeled antisense RNA probe. The DIG-labeled antisense
RNA probe was produced using a standard RNA labeling kit
(Roche Diagnostics) by using partial GPR147 cDNA (nt 302–716
in NM_022146) as a template. Defrosted sections were first fixed
in 4% paraformaldehyde (PFA) for 30 min. After washing the
sections three times in PBS, they were incubated in 1 mg/ml
proteinase K (Sigma-Aldrich, Saint Louis, MO) in PBS at 37uC for
30 min. Sections were fixed again in 4% PFA for 10 min, and then
treated with 0.2 N HCl for 10 min after rinsing the sections in
DEPC. The sections were again rinsed in DEPC twice and pre-
incubated in 50% deionized formamide in 5X SSC (Roche
Diagnostics) before the hybridization. Hybridization was carried
out overnight at 50uC in 50% deionized formamide, 50%
hybridization solution (2X concentrate, buffered with SSC,
Sigma-Aldrich) at the probe concentrations of 200 ng/ml. After
the hybridization, the sections were washed twice in 2X SCC in
50% formamide, and twice in 1X SSC in 50% formamide for
15 min each. After rinsing the sections in PBS, they were
incubated with alkaline phosphatase-labeled sheep anti-DIG
antibody (Roche Diagnostics) in 1.5% DIG blocking reagent
(Roche Diagnostics) in PBS. After rinsing the sections three times
in PBS and once in alkaline phosphate buffer (pH 9.5), the
immunoreactive product was visualized by immersing the sections
in a substrate solution (nitroblue tetrazolium/5-bromo-4-chloro-3-
indolyl phosphate stock solution; Roche Diagnostics) in alkaline
phosphate buffer. Control for specificity of in situ hybridization was
performed by using a DIG-labeled sense RNA probe, the sequence
of which was complementary to the antisense probe.
Immunocytochemical analyses of LH were further conducted
on the same sections previously labelled by in situ hybridization for
human GPR147 mRNA. After labeling human GPR147 mRNA,
the sections were washes in PBS three times and incubated
overnight at 4uC in a rabbit polyclonal anti-human LH antiserum,
(Affinity bioreagents, Golden, CO). The next day, after three
washes in PBS, the sections were incubated with goat anti-rabbit
IgG conjugated to Alexa Fluor 568 (Molecular Probes Inc.,
Eugene, OR).
Image processing
Microscopic images were acquired digitally on an Axio Imager,
A1 microscope (Carl Zeiss AG, Gottingen, Germany) with an
AxioCam MRc5 digital camera (Carl Zeiss AG) using AxioVision
Rel. 4.5 software package (Carl Zeiss AG). Fluorescent images
were excited by using HBO 100 microscope illuminating system
(Carl Zeiss AG). The brightness, contrast, sharpness and the size of
the images were adjusted using Adobe Photoshop CS2 (Adobe
Systems, San Jose, CA).
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